Expert perspectives on LAMA/LABA as first-line maintenance therapy and real life case studies
GSK interviewed respiratory experts Dr Daryl Freeman and Laura Rush to discuss the use of LAMA/LABAs as first-line maintenance therapy for appropriate symptomatic COPD patients and real life COPD case studies. The speakers were paid an honorarium for their time by GSK. Watch the videos below to learn more.
LAMA/LABAs as first-line maintenance therapy for appropriate symptomatic COPD patients
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.
PM-GB-UCV-WCNT-210008 May 2021